^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
In the absence of contraindications, the optimal chemotherapy to be combined with radiation in stage III NSCLC should be based on cisplatin or carboplatin [A ΒΌ 100% and I, A]. In a subset of older patients >70 years with stage III disease, carboplatin as monotherapy may be considered in combination with radiation [A [ 100% and I, B].
